Merck & Co., Inc. Proceeds from Divestiture of Interest in Joint Venture
Merck & Co., Inc. (MRK) reported Proceeds from Divestiture of Interest in Joint Venture of $647.00 million for the 9-month period ending 2010-09-30, per its 10-Q filed 2010-11-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDivestitureOfInterestInJointVenture · last filed 2010-11-08
- Merck & Co., Inc. proceeds from divestiture of interest in joint venture for the quarter ending 2010-09-30 was $0.00.
| Period end | Proceeds from Divestiture of Interest in Joint Venture 3 month | Proceeds from Divestiture of Interest in Joint Venture 6 month | Proceeds from Divestiture of Interest in Joint Venture 9 month |
|---|---|---|---|
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-08 | $647.00M 10-Q · filed 2010-11-08 | |
| 2010-06-30 | $647.00M 10-Q · filed 2010-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |